Will FCX Benefit From Tariffs?
Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…
Sell
50
BBIO Quote, Financials, Valuation and Earnings
Last price:
$47.10
Seasonality move
:
8.94%
Day range:
$46.70 - $47.66
52-week range:
$21.72 - $48.68
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
69.84x
P/B ratio:
--
Volume:
2.6M
Avg. volume:
3.2M
1-year change:
61.03%
Market cap:
$8.9B
Revenue:
$221.9M
EPS (TTM):
-$3.53
Analysts' Opinion
-
Consensus RatingBridgeBio Pharma has received a consensus rating of Buy. The company's average rating is a Buy based on 13 Buy ratings, 2 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $61.29, BridgeBio Pharma has an estimated upside of 30.12% from its current price of $47.10.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $41.00 representing 12.95% downside risk from its current price of $47.10.
Fair Value
-
According to the consensus of 15 analysts, BridgeBio Pharma has 30.12% upside to fair value with a price target of $61.29 per share.
BBIO vs. S&P 500
-
Over the past 5 trading days, BridgeBio Pharma has overperformed the S&P 500 by 2.37% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
BridgeBio Pharma does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
BridgeBio Pharma revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter BridgeBio Pharma reported revenues of $116.6M.
Earnings Growth
-
BridgeBio Pharma has grown year-over-year earnings for 0 quarters straight. In the most recent quarter BridgeBio Pharma reported earnings per share of -$0.88.
Enterprise value:
10.3B
EV / Invested capital:
--
Price / LTM sales:
69.84x
EV / EBIT:
--
EV / Revenue:
80.53x
PEG ratio (5yr expected):
-1.39x
EV / Free cash flow:
-20.14x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$121.5M
Return On Assets:
-81.27%
Net Income Margin (TTM):
-524.25%
Return On Equity:
--
Return On Invested Capital:
-145.93%
Operating Margin:
-89%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $77.8M | $218.6M | $127.4M | $211.1M | $116.6M | |
| Gross Profit | $75M | $216.2M | $121.5M | $210.5M | $114M | |
| Operating Income | -$440.2M | -$472.9M | -$684.9M | $3.7M | -$103.8M | |
| EBITDA | -$339.3M | -$455.6M | -$551.9M | -$11.1M | -$126.2M | |
| Diluted EPS | -$2.84 | -$3.22 | -$3.53 | -$0.20 | -$0.88 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $945.1M | $716.2M | $552.7M | $783.4M | $695.2M | |
| Total Assets | $1.1B | $813.1M | $625.7M | $849.3M | $881.6M | |
| Current Liabilities | $94.7M | $103.5M | $96.6M | $141.5M | $152.1M | |
| Total Liabilities | $1.5B | $1.9B | $1.8B | $1.9B | $2.5B | |
| Total Equity | -$388.1M | -$1B | -$1.2B | -$1B | -$1.6B | |
| Total Debt | $1.4B | $1.7B | $1.7B | $1.7B | $1.8B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$403.2M | -$602.9M | -$500.4M | -$219.5M | -$199.2M | |
| Cash From Investing | $326.8M | $64.5M | $36.4M | $22.8M | -$1.6M | |
| Cash From Financing | $137.3M | $580.8M | $529.2M | $279.5M | $60.3M | |
| Free Cash Flow | -$408.7M | -$605.7M | -$509.4M | -$221M | -$200.8M | |
BBIO
Sector
Market Cap
$8.9B
$34.5M
Price % of 52-Week High
96.75%
49.05%
Dividend Yield
0%
0%
Shareholder Yield
0.47%
-1.01%
1-Year Price Total Return
61.03%
-35.15%
Beta (5-Year)
1.154
0.615
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$45.90
200-day SMA
Buy
Level
$32.42
Bollinger Bands (100)
Buy
Level
32.44 - 41.12
Chaikin Money Flow
Buy
Level
9.4M
20-day SMA
Buy
Level
$44.14
Relative Strength Index (RSI14)
Buy
Level
70.28
ADX Line
Buy
Level
43.22
Williams %R
Neutral
Level
-22.9752
50-day SMA
Buy
Level
$39.18
MACD (12, 26)
Buy
Level
2.20
25-day Aroon Oscillator
Buy
Level
76
On Balance Volume
Neutral
Level
190.2M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-4.008)
Sell
CA Score
(Annual)
Level (-14.2071)
Sell
Beneish M-Score
(Annual)
Level (16.9075)
Buy
Momentum Score
Level (8)
Sell
Ohlson Score
Level (14.6583)
Buy
Piotroski F Score
(Annual)
Level (6)
Sell
Quality Ratio Score
Level (3)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
Stock Forecast FAQ
In the current month, BBIO has received 13 Buy ratings 2 Hold ratings, and 0 Sell ratings. The BBIO average analyst price target in the past 3 months is $61.29.
-
Where Will BridgeBio Pharma Stock Be In 1 Year?
According to analysts, the consensus estimate is that BridgeBio Pharma share price will rise to $61.29 per share over the next 12 months.
-
What Do Analysts Say About BridgeBio Pharma?
Analysts are divided on their view about BridgeBio Pharma share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that BridgeBio Pharma is a Sell and believe this share price will drop from its current level to $41.00.
-
What Is BridgeBio Pharma's Price Target?
The price target for BridgeBio Pharma over the next 1-year time period is forecast to be $61.29 according to 15 Wall Street analysts, 13 of them rate the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.
-
Is BBIO A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for BridgeBio Pharma is a Buy. 13 of 15 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of BBIO?
You can purchase shares of BridgeBio Pharma via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase BridgeBio Pharma shares.
-
What Is The BridgeBio Pharma Share Price Today?
BridgeBio Pharma was last trading at $47.10 per share. This represents the most recent stock quote for BridgeBio Pharma. Yesterday, BridgeBio Pharma closed at $47.10 per share.
-
How To Buy BridgeBio Pharma Stock Online?
In order to purchase BridgeBio Pharma stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Can Levi Stock Double?
Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…
How High Can SharkNinja Stock Go?
If you know popular consumer appliance brands Shark and Ninja,…
Stock Ideas
Buy
70
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 58x
Buy
62
Is MSFT Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 43x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Buy
89
EXOD alert for Jul 17
Exodus Movement [EXOD] is up 21.96% over the past day.
Buy
82
SBET alert for Jul 17
SharpLink Gaming [SBET] is up 28.58% over the past day.
Buy
60
U alert for Jul 17
Unity Software [U] is up 14.38% over the past day.
